Evaluating survival in patients with Adult T-cell leukemia and HTLV-1 infection
Caractérisation Clinico- Biologique et Survie Des Patients Porteurs d'Une lymphoprolifération HTLV-1 Induite (ou Lymphome/leucémie lié au Virus HTLV-1) et Des Patients infectés Par le Virus HTLV-1
Assistance Publique - Hôpitaux de Paris · NCT05237245
This study is trying to see how long people with Adult T-cell leukemia and those with the HTLV-1 virus live, to better understand the effects of the virus on their health.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 120 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Assistance Publique - Hôpitaux de Paris (other) |
| Locations | 1 site (Paris) |
| Trial ID | NCT05237245 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the survival outcomes of patients with Adult T-cell leukemia/lymphoma (ATL) and those chronically infected with the HTLV-1 virus. It consists of two cohorts: one group of ATL patients receiving various treatments and another group of HTLV-1 infected individuals without T lymphoproliferation. The study will collect and analyze clinical data to understand the impact of HTLV-1 on patient survival. The findings could provide insights into the disease progression and treatment efficacy for these conditions.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older who are infected with HTLV-1 and either have T lymphoproliferation or do not have it.
Not a fit: Patients who refuse participation or are under 18 years old will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance understanding of survival factors in ATL and HTLV-1 infected patients, potentially leading to improved treatment strategies.
How similar studies have performed: While there have been studies on HTLV-1 and ATL, this specific observational approach focusing on survival outcomes is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * 18 years old or older * HTLV-1 infected * T lymphoproliferation induced by HTLV-1 (cohort 1) * without T lymphoproliferation induced by HTLV-1 (cohort 2) * informed and accepted the collection of data Exclusion Criteria - Patients refusal of participation
Where this trial is running
Paris
- Hôpital Necker Enfants Malades — Paris, France (RECRUITING)
Study contacts
- Principal investigator: Ambroise MARCAIS, MD — Assistance Publique-Hôpitaux Paris
- Study coordinator: Ambroise MARCAIS, MD
- Email: ambroise.marcais@aphp.fr
- Phone: +33 1 44 49 46 99
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Lymphoproliferation Induced by HTLV-1, HTLV-1 Adult T-cell Lymphoma / Leukemia, HTLV-1 Infection, Human T-lymphotropic Virus 1, lymphoma, leukemia